Abeona Therapeutics (NASDAQ: ABEO) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk & Volatility

Abeona Therapeutics has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 2.78, meaning that its stock price is 178% more volatile than the S&P 500.

Valuation & Earnings

This table compares Abeona Therapeutics and Inovio Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics $842,999.00 652.33 -$23.80 million ($0.61) -22.38
Inovio Pharmaceuticals $51.84 million 10.20 -$70.60 million ($1.08) -5.43

Abeona Therapeutics has higher revenue, but lower earnings than Inovio Pharmaceuticals. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Abeona Therapeutics and Inovio Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics 0 0 6 0 3.00
Inovio Pharmaceuticals 0 2 7 0 2.78

Abeona Therapeutics currently has a consensus price target of $19.17, suggesting a potential upside of 40.42%. Inovio Pharmaceuticals has a consensus price target of $22.11, suggesting a potential upside of 277.32%. Given Inovio Pharmaceuticals’ higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Abeona Therapeutics.

Insider and Institutional Ownership

38.2% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 24.8% of Inovio Pharmaceuticals shares are held by institutional investors. 6.8% of Abeona Therapeutics shares are held by company insiders. Comparatively, 10.6% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Abeona Therapeutics and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Abeona Therapeutics -2,746.38% -26.66% -23.94%
Inovio Pharmaceuticals -153.46% -63.67% -46.77%

Summary

Abeona Therapeutics beats Inovio Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.